Ongoing Trials
Here you will find a list of all ongoing trials in NMSG with a short description and contact details for the principal investigator of the study. All NMSG members have access to the full protocol in the member area.
NMSG 26/19 – TOP75+
Full study name: RWD Working Group NMSG: Treatment and Outcome in MM Patients 75 and above
Principal investigator: Cecilie Hveding Bilmark
Type of study: Register study
Number of patients: 3000
Sites including patients: Denmark and Sweden
Synopsis: Not available yet
NMSG 27/19 – NOR-ASCT
Full study name: ASCT-Treatment in Nordic and Baltic MM Patients
Principal investigator: Cecilie Hveding Bilmark
Type of study: Register Study,
Number of patients: 2500
Sites including patients: NMSG countries
Synopsis: Not available yet
NMSG 25/16 - The CONPET study
KRd consolidation in myeloma patients with apositive PET-CT after standard first line treatment. A phase II study
Principal investigator: Fredrik Schjesvold
Type of study: Phase 2
Number of patients: 50
Sites including patients: Oslo, Odense, Bergen, Vejle, København, Lisboa
Click me for Synopsis
NMSG 23/15
Principal investigator: Raija Silvennoinen
Type of study: Phase II
Number of patients: 120
Sites including patients:
-
Finland: Helsinki, Turku, Tampere, Oulu, Kuopio, Kotka, Jyväskylä, Kajaani, Lahti
-
Norway: Trondheim, Oslo, Stavanger, Förde
-
Sweden: Stockholm, Lund, Uppsala, Göteborg, Örebro, Linköping, Sunderby Luleå, Helsingborg, Borås, Varberg, Uddevalla, Halmstad
-
Lithuanian: Vilnius
NMSG 22/14 The Magnolia Study
Prolonged Protection from Bone Disease in Multiple Myeloma. An open label phase 4 multicenter international randomised trial
Principal investigator: Thomas Lund
Type of study: Phase IV prospective randomised multicentre open-label study.
Number of patients: 358
NMSG 20/13 - CARFI
A phase 2 study of carfilzomib-cyclophosphamide-dexamethasone and high-dose melphalan followed by randomization between observation or maintenance with carfilzomib and dexamethasone in patients with relapsed multiple myeloma after high-dose melphalan with autologous stem cell support Principal investigator: Henrik Gregersen Type of study: Phase II Number of patients: 200 Sites including patients:
o Denmark: Aalborg, Aarhus, Herlev, Odense, Rigshospitalet, Roskilde.
o Finland: Kuopio, Oulu, Tampere, Turku.
o Norway: Oslo, Kristiansand. Trondheim
o Sweden: Helsingborg, Karolinska, Linköping, Lund, Sahlgrenska, Sunderbyn, Uddevalla, Umeå, Uppsala, Örebro.
o Lithuania: Vilnius
Status: Closed
HOVON 129/EMN 12 (collaborative study)
Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients.:
Principal investigator NMSG: Annette Vangsted
Type of study: Phase II, prospective, multicenter, intergroup
Number of patients: 116 Sites including patients in NMSG: Denmark (Aarhus, Odense, Rigshospitalet), Norway (Oslo and Trondheim)
Hovon 95/EMN (collaborative study)
A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple
Principal investigator: Dr. P. Sonneveld
Type of study: Phase III randomized.
Number of patients: 1500
Sites including patients: See synopsis
Status: Closed
Hovon 126 (collaborative study)
Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; a randomized phase II trial
Principal investigator: S. Zweegman (HOVON), N. Abildgaard (NMSG)
Type of study: Phase II
Number of patients: 142
Former and finalized studies
The NMSG has conducted 12 clinical trials the past 10 years. Here you find a list of the trials including a link to the main publication. In addition there are many spin-off studies based on these clinical trials.
-
MP-T + Thal maintenance vs. MP-R + Rev maintenance as first line treatment in elderly newly diagnosed (phase III, NMSG-HOVON-study)
Publications:
-
Zweegman et al, Blood. 2016 Mar 3;127(9):1109-16 [https://www.ncbi.nlm.nih.gov/pubmed/26802176]
-
NOP in refractory myeloma (phase II) and newly diagnosed myeloma (phase III)
Publications:
-
Gimsing et al. Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG). Br J Haematol. 1991 Jan;77(1):73-9.
-
Wisløff et al. Bolus therapy with mitoxantrone and vincristine in combination with high-dose prednisone (NOP-bolus) in resistant multiple myeloma. Nordic Myeloma Study Group (NMSG). Eur J Haematol. 1992 Feb;48(2):70-4.
-
Keldsen et al. Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG).Eur J Haematol. 1993 Aug;51(2):80-5.
-
MP vs. MP+IFNa (phase III)
Publications:
-
Wisløff F, et al.Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol. 1996 Mar;92(3):604-13. DOI:10.1046/j.1365-2141.1996.352889.x
-
Wisløff F, et al.Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. Br J Haematol. 1996 Aug;94(2):324-32. DOI:10.1046/j.1365-2141.1996.d01-1802.x
-
Wisløff et al. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol. 1997 Apr;97(1):29-37. DOI: 10.1046/j.1365-2141.1997.222667.x
-
High-dose chemotherapy + stem cell support in patients < 60 years (vs. historical control)
Publications:
-
Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000 Jan 1;95(1):7-11.
-
Lenhoff S, Hjorth M, Westin J, Brinch L, Backstrom B, Carlson K, et al. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol 2006 May;133(4):389-96. DOI: 10.1111/j.1365-2141.2006.06042.x
-
High-dose chemotherapy + stem cell support in patients < 65 years (vs. historical control)
Publications:
-
Mellqvist et al, Cancer. 2008 Jan 1;112(1):129-35. [https://www.ncbi.nlm.nih.gov/pubmed/17973267]
-
Induction chemotherapy VAD vs. Cy-Dex (phase III)
Publications:
-
Mellqvist et al, Cancer. 2008 Jan 1;112(1):129-35. [https://www.ncbi.nlm.nih.gov/pubmed/17973267]
-
Induction chemotherapy Cy-Fludarabin-Dex vs. Cy-Dex (phase II)
Publications:
-
HE Johnsen, LM Knudsen, AK Mylin, P Gimsing, H Gregersen, N Abildgaard, JL Nielsen, N Frost Andersen, T Plesner, A Vangsted, T Mourits-Andersen. Impaired stem cell mobilization by adding fludarabine to cyclophophamide-dexamethason induction therapy in multiple myeloma patients. Report from the NMSG #13/03 sponsored randomized, placebo controlled trial. Hematology Reviews, vol 1; 62-64. 2009
-
MP vs. MP-T in elderly newly diagnosed (phase III)
Publications:
-
Waage et al, Blood. 2010 Sep 2;116(9):1405-12 [https://www.ncbi.nlm.nih.gov/pubmed/20448107]
-
Pamidronate 90 mg vs. 30 mg in bone protection (phase III)
Publications:
-
Gimsing et al Lancet Oncol. 2010 Oct;11(10):973-82 [https://www.ncbi.nlm.nih.gov/pubmed/20863761]
-
Bortezomib-Dex vs. Thalidomide-Dex in first relapse (phase III)
Publications:
-
Hjorth et al, Eur J Haematol. 2012 Jun;88(6):485-96. [https://www.ncbi.nlm.nih.gov/pubmed/22404182]
-
Bortezomib consolidation vs. no consolidation post-ASCT (phase III)
Publications:
-
Mellqvist et al, Blood. 2013 Jun 6;121(23):4647-54. [https://www.ncbi.nlm.nih.gov/pubmed/23616624]
-
Bortezomib-Dex re-induction followed by Bortezomib+Melfalan conditioning and ASCT in first relaps after prior ASCT (phase II)
Publications:
-
Gimsing et al, Bone Marrow Transplant. 2015 Oct; 50(10): 1306–1311 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598614/]